Untitled

Abstract

We compared plasma content of soluble Fas antigen (sFas) in 59 patients with tumors and tumor-like pathologies of the adrenal cortex and medulla and 60 healthy donors (control). The incidence and content of sFas in the plasma from patients with adrenal tumors was significantly higher than in healthy donors. A direct correlation was found between sFas content and patient's age. The maximum sFas concentrations were found in patients with pheochromocytoma and aldosterone-producing adenoma. In patients with adrenocortical cancer plasma content of sFas was lower than in patients with tumors of other morphological types. Plasma sFas content in patients with adrenocortical cancer directly correlated with the size of tumors. Our results suggest that sFas plays a role in the pathogenesis of primary adrenal tumors.

Apoptosis regulation in adrenocortical carcinoma

“…sFas plasma levels were particularly higher in patients with aldosterone producing adenomas. In addition, sFas plasma levels were positively correlated with the ACC size (31, 32). In childhood ACT, Fas gene expression was lower in ACT when compared with normal adrenal glands, but no differences were observed between ACC and ACA (24).…”

Epitope mapping of human Fas using peptide phage display

“…High levels of sFas were observed in malignant tumors of the bones (osteogenic sarcoma, chondrosarcoma, Ewing's tumor), in ovarian cancer, breast cancer, gastric and colorectal cancer, prostatic, adrenal, and thyroid cancers [1][2][3][4][5][6]. High levels of serum sFas in cancer patients were associated with unfavorable prognosis.…”